Advertisement
 
YOU ARE HERE: LAT HomeCollectionsNeurontin Drug
IN THE NEWS

Neurontin Drug

FEATURED ARTICLES
BUSINESS
April 29, 2004 | From Reuters
Generic drug makers Teva Pharmaceutical Industries Ltd. and Alpharma Inc. said they agreed to share revenue from generic versions of Pfizer Inc.'s top-selling epilepsy drug, Neurontin. Alpharma would have a six-month U.S. generic exclusivity period for copycat capsules and perhaps for copycat tablets if generic drug makers win their court battles with Pfizer. Shares of Alpharma jumped $3.10 to $24 on the NYSE, while shares of Teva rose 40 cents to $66.17 on Nasdaq. From Reuters
ARTICLES BY DATE
BUSINESS
August 24, 2005 | From Bloomberg News
Generic-drug makers including Ivax Corp. and Teva Pharmaceutical Industries Ltd. aren't infringing patents on Pfizer Inc.'s epilepsy drug Neurontin by selling low-cost versions, a federal judge ruled. U.S. District Judge John Lifland in Newark, N.J., said the generic version of gabapentin, the key ingredient in Neurontin, didn't infringe. Pfizer will appeal, spokesman Paul Fitzhenry said. Teva, Ivax and Alpharma Inc.
Advertisement
BUSINESS
August 24, 2005 | From Bloomberg News
Generic-drug makers including Ivax Corp. and Teva Pharmaceutical Industries Ltd. aren't infringing patents on Pfizer Inc.'s epilepsy drug Neurontin by selling low-cost versions, a federal judge ruled. U.S. District Judge John Lifland in Newark, N.J., said the generic version of gabapentin, the key ingredient in Neurontin, didn't infringe. Pfizer will appeal, spokesman Paul Fitzhenry said. Teva, Ivax and Alpharma Inc.
BUSINESS
April 29, 2004 | From Reuters
Generic drug makers Teva Pharmaceutical Industries Ltd. and Alpharma Inc. said they agreed to share revenue from generic versions of Pfizer Inc.'s top-selling epilepsy drug, Neurontin. Alpharma would have a six-month U.S. generic exclusivity period for copycat capsules and perhaps for copycat tablets if generic drug makers win their court battles with Pfizer. Shares of Alpharma jumped $3.10 to $24 on the NYSE, while shares of Teva rose 40 cents to $66.17 on Nasdaq. From Reuters
BUSINESS
May 29, 2003 | From Associated Press
The U.S. government is supporting a whistle-blower who sued Pfizer Inc. and its subsidiary Parke-Davis, saying evidence backs his claim that the drug maker illegally marketed the epilepsy drug Neurontin and offered lavish kickbacks to doctors. U.S. Atty. Michael Sullivan has filed a "statement of interest" in David Franklin's civil lawsuit in federal court, arguing against the pharmaceutical company's motion to have the lawsuit thrown out.
BUSINESS
May 29, 2003 | From Associated Press
The U.S. government is supporting a whistle-blower who sued Pfizer Inc. and its subsidiary Parke-Davis, saying evidence backs his claim that the drug maker illegally marketed the epilepsy drug Neurontin and offered lavish kickbacks to doctors. U.S. Atty. Michael Sullivan has filed a "statement of interest" in David Franklin's civil lawsuit in federal court, arguing against the pharmaceutical company's motion to have the lawsuit thrown out.
Los Angeles Times Articles
|